ResMed Inc. $RMD Stake Raised by First Trust Advisors LP

First Trust Advisors LP increased its holdings in shares of ResMed Inc. (NYSE:RMD – Free Report) by 18.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,688,777 shares of the medical equipment provider’s stock after buying an additional 410,081 shares during the period. First Trust Advisors LP owned 1.91% of ResMed worth $594,489,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of ResMed in the 2nd quarter valued at $2,400,375,000. State Street Corp increased its holdings in ResMed by 0.6% in the second quarter. State Street Corp now owns 6,680,735 shares of the medical equipment provider’s stock valued at $1,301,942,000 after purchasing an additional 37,567 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in ResMed in the second quarter valued at about $818,030,000. Deutsche Bank AG acquired a new position in ResMed in the second quarter valued at about $257,692,000. Finally, Amundi lifted its stake in ResMed by 123.9% in the first quarter. Amundi now owns 1,062,184 shares of the medical equipment provider’s stock valued at $238,439,000 after buying an additional 587,872 shares during the period. 54.98% of the stock is currently owned by institutional investors and hedge funds.

ResMed Stock Performance

Shares of ResMed stock opened at $235.78 on Friday. The firm has a market cap of $33.16 billion, a price-to-earnings ratio of 21.47, a price-to-earnings-growth ratio of 1.43 and a beta of 0.77. The stock’s 50-day moving average is $233.90 and its 200-day moving average is $223.98. ResMed Inc. has a one year low of $180.26 and a one year high of $277.67. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.65 and a quick ratio of 1.88.

ResMed (NYSE:RMD – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The medical equipment provider reported $2.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.67 by $0.24. The business had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.39 billion. ResMed had a return on equity of 26.42% and a net margin of 27.79%. ResMed’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period last year, the company earned $2.55 earnings per share. Equities analysts predict that ResMed Inc. will post 12.14 earnings per share for the current fiscal year.

ResMed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 17th. Stockholders of record on Thursday, November 12th will be paid a dividend of $0.66 per share. This represents a $2.64 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Thursday, November 12th. ResMed’s dividend payout ratio (DPR) is currently 24.04%.

Analysts Set New Price Targets

RMD has been the subject of several analyst reports. Royal Bank Of Canada boosted their target price on ResMed from $262.00 to $288.00 and gave the stock an “outperform” rating in a research report on Friday, October 30th. Weiss Ratings upgraded shares of ResMed from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday. Mizuho set a $270.00 target price on shares of ResMed in a research note on Friday, October 30th. Robert W. Baird set a $213.00 target price on shares of ResMed in a report on Friday, August 7th. Finally, Piper Sandler cut their target price on shares of ResMed from $233.00 to $225.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $253.69.

Read Our Latest Stock Report on RMD

Insider Buying and Selling at ResMed

In related news, General Counsel Michael Rider sold 400 shares of the stock in a transaction on Friday, October 23rd. The shares were sold at an average price of $255.00, for a total transaction of $102,000.00. Following the completion of the transaction, the general counsel owned 12,318 shares in the company, valued at approximately $3,141,090. This represents a 3.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Farrell sold 4,993 shares of ResMed stock in a transaction on Monday, November 9th. The shares were sold at an average price of $235.35, for a total transaction of $1,175,102.55. Following the completion of the sale, the chief executive officer owned 479,803 shares in the company, valued at $112,921,636.05. The trade was a 1.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 16,774 shares of company stock valued at $3,846,275 over the last quarter. Insiders own 0.58% of the company’s stock.

ResMed Company Profile

(Free Report)

ResMed is a medical technology company that develops products and software for people with sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its devices include continuous positive airway pressure (CPAP) and bilevel machines, ventilators and related masks and accessories. The company also provides cloud-connected software for managing sleep and respiratory care, along with digital tools used by home medical equipment providers and post-acute care organizations.

Read More

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD – Free Report).

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.